Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHST BioHarvest Sciences	$6.35	$6.17	$6.31 ▼ $7.38	$104.30M	0.8	17,153 shs	9,173 shs
CGTX Cognition Therapeutics	$0.24 +0.2%	$0.37	$0.22 ▼ $2.54	$15.13M	1	2.61 million shs	495,451 shs
COYA Coya Therapeutics	$5.40 -3.7%	$5.92	$4.65 ▼ $10.24	$91.57M	0.49	72,380 shs	27,418 shs
VXRT Vaxart	$0.46 +2.9%	$0.40	$0.29 ▼ $1.07	$105.67M	1.27	2.43 million shs	818,187 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHST BioHarvest Sciences	+1.60%	+4.10%	+1.44%	+22.35%	+634,999,900.00%
CGTX Cognition Therapeutics	-5.76%	-23.47%	-41.51%	-46.85%	-88.93%
COYA Coya Therapeutics	-1.58%	-1.23%	-9.24%	-16.79%	-27.93%
VXRT Vaxart	-2.36%	-1.60%	+0.63%	-8.63%	-45.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	3.0224 of 5 stars	3.5	3.0	0.0	0.0	2.4	2.5	1.3
COYA Coya Therapeutics	2.4207 of 5 stars	3.5	5.0	0.0	0.0	2.5	0.8	0.0
VXRT Vaxart	2.6492 of 5 stars	3.5	3.0	0.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHST BioHarvest Sciences	3.00	Buy	$13.67	115.22% Upside
CGTX Cognition Therapeutics	3.00	Buy	$5.63	2,205.33% Upside
COYA Coya Therapeutics	3.00	Buy	$17.00	215.11% Upside
VXRT Vaxart	3.00	Buy	$3.00	547.95% Upside

Current Analyst Ratings Breakdown

Latest CGTX, COYA, BHST, and VXRT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/8/2025	BHST BioHarvest Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/27/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/27/2025	VXRT Vaxart	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.50 ➝ $2.00
3/24/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
3/21/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHST BioHarvest Sciences	$27.70M	3.76	N/A	N/A	($1.08) per share	-5.88
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.76 per share	N/A
COYA Coya Therapeutics	$3.69M	24.49	N/A	N/A	$2.47 per share	2.18
VXRT Vaxart	$47.40M	2.23	N/A	N/A	$0.38 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHST BioHarvest Sciences	-$12.56M	-$0.50	N/A	N/A	N/A	-76.65%	N/A	-85.16%	5/29/2025 (Estimated)
CGTX Cognition Therapeutics	-$25.79M	-$0.74	N/A	N/A	N/A	N/A	-150.93%	-100.82%	8/14/2025 (Estimated)
COYA Coya Therapeutics	-$7.99M	-$1.07	N/A	N/A	N/A	N/A	-31.63%	-27.76%	8/11/2025 (Estimated)
VXRT Vaxart	-$82.46M	-$0.27	N/A	N/A	N/A	-431.61%	-110.46%	-62.78%	8/14/2025 (Estimated)

Latest CGTX, COYA, BHST, and VXRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$7.80 million	$7.64 million
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/13/2025	Q1 2025	VXRT Vaxart	-$0.07	-$0.07	N/A	-$0.07	$2.85 million	$20.88 million
5/6/2025	Q1 2025	CGTX Cognition Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A
3/31/2025	Q4 2024	BHST BioHarvest Sciences	-$0.12	-$0.17	-$0.05	-$0.17	$7.24 million	$7.17 million
3/20/2025	Q4 2024	CGTX Cognition Therapeutics	-$0.16	-$0.17	-$0.01	-$0.17	N/A	N/A
3/20/2025	Q4 2024	VXRT Vaxart	-$0.10	-$0.05	+$0.05	-$0.05	$15.68 million	$15.19 million
3/18/2025	Q4 2024	COYA Coya Therapeutics	-$0.32	-$0.18	+$0.14	-$0.18	$0.10 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHST BioHarvest Sciences	N/A	0.80	0.48
CGTX Cognition Therapeutics	N/A	2.11	2.11
COYA Coya Therapeutics	N/A	15.31	15.31
VXRT Vaxart	N/A	0.83	0.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHST BioHarvest Sciences	N/A
CGTX Cognition Therapeutics	43.35%
COYA Coya Therapeutics	39.75%
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
BHST BioHarvest Sciences	N/A
CGTX Cognition Therapeutics	20.75%
COYA Coya Therapeutics	12.00%
VXRT Vaxart	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
CGTX Cognition Therapeutics	20	61.99 million	32.93 million	Not Optionable
COYA Coya Therapeutics	6	16.73 million	14.70 million	Not Optionable
VXRT Vaxart	120	228.22 million	221.57 million	Optionable

CGTX, COYA, BHST, and VXRT Headlines

Recent News About These Companies

Vaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025

May 29 at 8:32 AM | quiverquant.com

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29 at 8:00 AM | globenewswire.com

Vaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - What's Next?

May 29 at 5:10 AM | marketbeat.com

Vaxart Discusses Reverse Stock Split and Capital Raise

May 28 at 3:41 PM | tipranks.com

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28 at 8:00 AM | globenewswire.com

Vaxart (NASDAQ:VXRT) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI) Head to Head Contrast

May 28 at 2:07 AM | americanbankingnews.com

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27 at 8:00 AM | globenewswire.com

Vaxart (NASDAQ:VXRT) Raised to Hold at Wall Street Zen

May 25, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Vaxart (NASDAQ:VXRT) to "Hold"

May 24, 2025 | marketbeat.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman

May 20, 2025 | quiverquant.com

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock News

May 20, 2025 | gurufocus.com

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2025 | globenewswire.com

Vaxart, Inc. (NASDAQ:VXRT) Insider Steven Lo Acquires 100,000 Shares

May 20, 2025 | insidertrades.com

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

May 16, 2025 | globenewswire.com

Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - Here's What Happened

May 16, 2025 | marketbeat.com

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 15, 2025 | globenewswire.com

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

May 14, 2025 | globenewswire.com

Vaxart Names Grasman as CFO, Succeeding Lee

May 14, 2025 | marketwatch.com

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, COYA, BHST, and VXRT Company Descriptions

BioHarvest Sciences NASDAQ:BHST

$6.35 0.00 (0.00%)

As of 01:33 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Cognition Therapeutics NASDAQ:CGTX

$0.24 +0.00 (+0.16%)

As of 03:18 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Coya Therapeutics NASDAQ:COYA

$5.40 -0.21 (-3.66%)

As of 03:19 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Vaxart NASDAQ:VXRT

$0.46 +0.01 (+2.89%)

As of 03:19 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time